EloquiMed Logo

Clinical Protocol Development

Expert development of clear, compliant, and scientifically sound clinical trial protocols to drive your drug development success.

Clinical protocol development

Comprehensive Protocol Development Solutions

Clinical trial protocols are the foundation of a successful study and regulatory submission. EloquiMed specializes in developing scientifically sound, operationally feasible, and regulatory-compliant protocols for all phases of clinical development.

Protocol Development That Delivers:

Scientifically Rigorous

Thorough scientific rationale and robust methodology that withstands regulatory scrutiny.

Operationally Feasible

Practical protocols that balance scientific rigor with real-world implementation considerations.

Regulatory Compliant

Adherence to ICH, FDA, EMA and other regulatory guidelines and requirements.

Publication Ready

Clear methodology and design elements ready for future publication considerations.

Our experienced medical writers work closely with your clinical and scientific teams to create protocols that:

  • Clearly articulate scientific rationale and study objectives
  • Define precise eligibility criteria and endpoints aligned with development goals
  • Incorporate appropriate statistical methodologies and analysis plans
  • Address potential risks with comprehensive safety monitoring plans
  • Meet regulatory requirements across global regions
  • Optimize operational feasibility while maintaining scientific rigor

Our Protocol Development Services

Comprehensive solutions for all types of protocols across the clinical development lifecycle

Phase I Protocols

Expert development of FIH, SAD/MAD, food effect, DDI, and other early phase protocols with appropriate safety monitoring and stopping criteria.

Phase II Protocols

Strategically designed dose-finding, POC, and early efficacy protocols with appropriate endpoints and biomarker strategies.

Phase III Protocols

Comprehensive pivotal trial protocols with robust design, appropriate endpoints, and statistical power to support registration.

Phase IV Protocols

Post-approval study protocols including PASS, PAES, registry studies, and real-world evidence generation.

Our Protocol Development Approach

A collaborative, structured process ensuring scientifically sound, operationally feasible protocols

01
Needs Assessment

Thorough understanding of study objectives, development strategy, target population, and regulatory requirements.

02
Scientific Input

Collaboration with clinical, scientific, statistical, and operational stakeholders to define key elements.

03
Drafting

Development of protocol by specialized medical writers with therapeutic area expertise and regulatory knowledge.

04
Review & Refinement

Iterative review process with all stakeholders to ensure scientific accuracy, clarity, and operational feasibility.

05
Finalization

Quality control with regulatory compliance check, editorial review, and final formatting for implementation.

Protocol excellence components

Elements of Protocol Excellence

EloquiMed's protocol development incorporates key elements that ensure both scientific rigor and operational success.

Clear Scientific Rationale
Strong foundation of scientific evidence and clear articulation of study hypotheses and objectives.
Precise Eligibility Criteria
Well-defined inclusion/exclusion criteria that balance scientific rigor with recruitment feasibility.
Appropriate Endpoints
Carefully selected primary, secondary, and exploratory endpoints aligned with study objectives and regulatory requirements.
Robust Statistical Methods
Clear statistical methodology, sample size justification, and analysis plans to support study conclusions.
Comprehensive Safety Monitoring
Detailed safety assessments, stopping rules, and risk mitigation strategies appropriate for study phase and product profile.

Case Study: Complex Protocol Development

How EloquiMed developed an innovative adaptive protocol for a challenging rare disease program

Challenge

A biotech company was developing a novel therapy for a rare neurodegenerative disease with significant heterogeneity. The client needed a protocol that could accommodate the small patient population, address multiple primary endpoints, and incorporate biomarker-driven stratification—all while meeting global regulatory requirements.

Adaptive Design Strategy
Developed a seamless Phase 2/3 adaptive design with interim analyses for sample size re-estimation and cohort enrichment.
Innovative Endpoint Approach
Created a novel composite endpoint strategy with Bayesian analytical framework to maximize information from limited patients.
Biomarker Integration
Incorporated comprehensive biomarker strategy for patient stratification and as supportive endpoints.
Patient-Centric Design
Implemented decentralized elements to reduce patient burden and maximize recruitment in this rare population.
100%
Regulatory acceptance across US, EU, and Japan
30%
Reduction in required sample size
15+
Sites adopted the protocol with minimal queries
4 weeks
Time from concept to final protocol
“EloquiMed transformed our complex clinical development challenge into an elegant protocol that satisfied both scientific and regulatory requirements. Their strategic thinking and clear writing were instrumental to our successful study initiation.”
Clinical Development Director, Biotech Client

Protocol Development Across Therapeutic Areas

Our therapeutic area specialists ensure protocols meet the unique requirements of each field

Oncology
Expert development of complex oncology protocols including innovative trial designs (basket, umbrella, platform), appropriate endpoints (ORR, PFS, OS), and specialized assessments (RECIST, iRECIST).
Immunology/Inflammation
Protocols for autoimmune and inflammatory conditions with appropriate stratification, specialized assessment scales, and biomarker strategies.
Neurology
Specialized protocols for neurodegenerative, psychiatric, and pain indications with appropriate cognitive and functional assessments, and innovative trial designs.
Rare Diseases
Innovative protocol designs for small patient populations, including natural history components, novel endpoints, and creative statistical approaches.
Cardiovascular & Metabolic
Protocols for CV outcome trials, diabetes, dyslipidemia, and other cardiometabolic conditions with appropriate composite endpoints and risk factor stratification.
Infectious Diseases
Protocol development for antimicrobials, antivirals, vaccines, and other infectious disease therapeutics with appropriate microbiological assessments.

Frequently Asked Questions

Common questions about our protocol development services

How long does protocol development take?

Timeline depends on study complexity and client review cycles. Typically, we deliver standard protocols within 3-6 weeks from kickoff to final version, with expedited options available for urgent needs.

Can you work with our existing templates?

Yes, we can work with your existing templates or develop custom ones aligned with your corporate style. We ensure all regulatory requirements are met regardless of the template format.

How do you handle statistical sections?

We collaborate closely with your statisticians or our statistical consultants to develop appropriate statistical methodologies, sample size calculations, and analysis plans aligned with study objectives.

Do you support health authority interactions?

Yes, we can prepare protocol synopses and other documentation for health authority interactions, as well as address protocol-related questions that arise during regulatory reviews.

Ready to develop your next clinical protocol?

Contact EloquiMed today to discuss how our protocol development experts can support your clinical development program.

Related Services

Clinical Study Reports
Comprehensive, ICH E3-compliant CSRs that effectively communicate your study results to regulatory authorities.
Investigator Brochures
Comprehensive, scientifically rigorous IBs that effectively communicate your product's profile to clinical investigators.
Regulatory Submissions
Expert development of regulatory documentation for successful submissions across global markets.